Dexamethasone in Tuberculous Meningitis

Introduction to Dexamethasone Use

The American Thoracic Society recommends adjunctive dexamethasone for all patients with tuberculous meningitis, particularly those with decreased level of consciousness, as it reduces mortality and neurological sequelae 1, 2, 3

For adults and children ≥25 kg, the recommended dose is 12 mg/day for 3 weeks, then taper over the following 3 weeks, according to the American Journal of Respiratory and Critical Care Medicine 1, 2, 3
For children <25 kg, the recommended dose is 8 mg/day for 3 weeks, then taper over the following 3 weeks, as suggested by the American Journal of Respiratory and Critical Care Medicine 1, 2, 3

The American Journal of Respiratory and Critical Care Medicine suggests initiating dexamethasone before or concurrently with the first dose of anti-tuberculosis medication to maximize benefit by attenuating the inflammatory cascade before it fully develops 4

Six of eight controlled trials demonstrated benefit in terms of survival, frequency of sequelae, or both, with the greatest mortality benefit observed in patients with Stage II disease, according to the American Journal of Respiratory and Critical Care Medicine 1, 2, 3
The mortality rate was 15% with dexamethasone versus 40% in controls (p<0.02) for Stage II disease, as reported by the American Journal of Respiratory and Critical Care Medicine 1, 2, 3

The initial 2-month phase should include INH, RIF, PZA, and EMB, followed by a continuation phase with INH and RIF for an additional 7-10 months, as recommended by the American Journal of Respiratory and Critical Care Medicine 1, 3
The total treatment duration is 9-12 months, though optimal duration is not definitively established, according to the American Journal of Respiratory and Critical Care Medicine 1, 3

Repeated lumbar punctures should be considered to monitor CSF cell count, glucose, and protein, especially early in therapy, as suggested by the American Journal of Respiratory and Critical Care Medicine 1, 3